Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2022-09-14 00:00:00 ET · period of report 2022-09-12 · accession 0001209191-22-049938 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-14 | 2022-09-12 | OVID | Tardio Jason | COO | S - Sale | $2.15 | -17.3K | 0 | -100% | -$37.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-12 | S | D | 17,344 | $2.15 | 0 | D | — | — | (F1) The Reporting Person acquired the shares pursuant to the Issuer's employee stock purchase plan. These transactions were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Following the reported transaction, the Reporting Person will hold no ESPP shares. |